Enlivex Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Oren Hershkovitz
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | n/a | n/a | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | n/a | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$296k | US$38k | -US$10m |
Compensation vs Market: Insufficient data to establish whether Oren's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.
CEO
Oren Hershkovitz (47 yo)
5yrs
Tenure
US$295,600
Compensation
Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 994.6k | |
| Chief Executive Officer | 5yrs | US$295.60k | 0.12% $ 32.8k | |
| Chief Financial Officer | 8.8yrs | US$132.00k | 0.0088% $ 2.4k | |
| Senior Director of Operations | 2.8yrs | no data | no data | |
| Director of HR | 2.8yrs | no data | no data |
5.0yrs
Average Tenure
47yo
Average Age
Experienced Management: ENLV's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 994.6k | |
| Independent Director | 1.6yrs | no data | no data | |
| Independent Director | 10.8yrs | no data | 0.85% $ 232.9k | |
| Clinical Advisor | no data | no data | no data | |
| Independent Vice Chairman of the Board | 2.5yrs | no data | 0% $ 0 | |
| Director | 3.9yrs | no data | 0.013% $ 3.5k | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | less than a year | no data | no data | |
| Clinical Advisor | less than a year | no data | no data | |
| Independent Director | 10.8yrs | no data | 0.024% $ 6.5k | |
| Clinical Advisor | less than a year | no data | no data | |
| Clinical Advisor | less than a year | no data | no data |
2.0yrs
Average Tenure
60yo
Average Age
Experienced Board: ENLV's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.